AM Best revises UniMed outlook to stable, affirms ratings in New Zealand

AM Best revises UniMed outlook to stable, affirms ratings in New Zealand
UniMed outlook now stable

New Zealand health insurer Union Medical Benefits Society Limited, known as UniMed, is seeing pressure on its credit profile ease as underwriting measures support a steadier operating trajectory. The ratings action keeps the insurer’s Financial Strength Rating at A and its Long-Term Issuer Credit Rating at “a”, while signaling improved near-term stability after losses in fiscal 2024 and 2025.

Highlights

  • AM Best revised UniMed's outlook to stable from negative and affirmed its A Financial Strength Rating, citing improved underwriting trend and reduced balance sheet pressure.
  • Recent portfolio remediation, including premium rate increases, reversed two years of operating losses in fiscal 2024 and 2025 caused by high claim inflation in New Zealand.
  • AM Best noted UniMed's strongest risk-adjusted capitalisation and above-peer solvency, while investments in technology and marketing aim to drive accelerated growth and customer retention.

Ratings action reflects improved underwriting trend

As reported by AM Best, the agency has revised UniMed’s outlooks to stable from negative and affirmed its Financial Strength Rating of A and Long-Term Issuer Credit Rating of “a”. The agency says the ratings reflect UniMed’s very strong balance sheet strength, along with adequate operating performance, a neutral business profile and appropriate enterprise risk management.

AM Best says the outlook revision follows an improvement in operating performance metrics in recent periods, which reduces pressure on the insurer’s balance sheet strength fundamentals. It adds that recent underwriting performance benefits from portfolio remediation actions, including premium rate increases, after two consecutive years of operating losses in fiscal 2024 and 2025 tied to persistent high claim inflation in New Zealand. Prospectively, the agency expects operating performance to remain supportive of the adequate assessment.

AM Best also says UniMed’s balance sheet strength is underpinned by the strongest level of risk-adjusted capitalisation, as measured by Best’s Capital Adequacy Ratio, despite a declining trend driven mainly by recent operating losses. The assessment also factors in low underwriting leverage, moderate investment risk and a regulatory solvency position that remains above industry peers and the insurer’s internal minimum threshold.

Market position and growth plans in focus

As a member-owned organisation, UniMed has limited financial flexibility, according to AM Best. The agency says that constraint is partly offset by a prudent capital management strategy focused on maintaining sufficient capital buffers.

AM Best assesses UniMed’s business profile as neutral and says the insurer has maintained a defensible position as New Zealand’s third-largest player in health insurance. While its monoline, not-for-profit model limits product diversification, the company benefits from relatively low product risk and limited exposure to large-loss and catastrophe events.

Looking ahead, AM Best says ongoing investments in technology and marketing are expected to support UniMed’s next phase of accelerated growth and customer retention. That outlook suggests the insurer is seeking to strengthen its competitive position in New Zealand’s health insurance sector while preserving capital resilience.

Our earlier article on Fitch’s rating action for Sansar Sep 2024 Trust explained that stronger credit support and stable asset performance helped keep the trust’s pass-through certificates at an investment-grade level with a Stable Outlook. It also noted that while downgrade risk eased as credit-enhancement buffers built, further upgrades were unlikely due to transaction documentation caps tied to the minimum ratings of guarantee providers.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.